一项为期 24 个月的安慰剂对照、双盲、平行组研究,评估 E2609 对患有早期阿尔茨海默症之受试者的有效性和安全性
[Translation] A 24-month placebo-controlled, double-blind, parallel-group study evaluating the efficacy and safety of E2609 in subjects with early Alzheimer's disease
本研究的主要目的是根据早期阿尔茨海默症 (EAD) 受试者在第 24 个月时临床痴呆综合汇总评定量表 (CDR-SB) 评分相比基线的变化,确定 E2609是否优于安慰剂。
[Translation] The primary objective of this study was to determine whether E2609 was superior to placebo based on the change from baseline in the Clinical Dementia Rating Summary (CDR-SB) score at month 24 in subjects with early Alzheimer's disease (EAD).
一项为期 24 个月的安慰剂对照、双盲、平行组研究,评估 E2609 对患有早期阿尔茨海默症之受试者的有效性和安全性
[Translation] A 24-month placebo-controlled, double-blind, parallel-group study evaluating the efficacy and safety of E2609 in subjects with early Alzheimer's disease
本研究的主要目的是根据早期阿尔茨海默症 (EAD) 受试者在第 24 个月时临床痴呆综合汇总评定量表 (CDR-SB) 评分相比基线的变化,确定 E2609是否优于安慰剂。
[Translation] The primary objective of this study was to determine whether E2609 was superior to placebo based on the change from baseline in the Clinical Dementia Rating Summary (CDR-SB) score at month 24 in subjects with early Alzheimer's disease (EAD).
100 Clinical Results associated with Sinus Pharmaceutical Consulting (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Sinus Pharmaceutical Consulting (Shanghai) Co., Ltd.
100 Deals associated with Sinus Pharmaceutical Consulting (Shanghai) Co., Ltd.
100 Translational Medicine associated with Sinus Pharmaceutical Consulting (Shanghai) Co., Ltd.